Additionally, the discovery of synthetic lethality involving Wnt signaling suggests that CTNNB1-mutant cancers may be vulnerable to combination therapies targeting other pathways that intersect with Wnt signaling, such as the PI3K/AKT/mTOR pathway [99]. The gene discussed is AKT1; the disease is cancer.